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Background: Intimate partner violence (IPV) has been associated with HIV susceptibility and 
acquisition. Studies have found that women who had experienced IPV were at least three times 
more likely to have a diagnosis of HIV. Women are interested in taking PrEP, however barriers 
to uptake, adherence, and persistence are not widely known, and present knowledge excludes 
experiences of healthcare providers and IPV service providers. In this qualitative study, we 
examined the perceived facilitators and possible solutions to PrEP uptake, adherence, and 
persistence. This was done using a sample of women experiencing IPV, Reproductive Health 
Providers, PrEP Providers, and IPV service providers. Methods: We conducted semi-structured 
interviews with 19 women experiencing IPV, 5 Reproductive Health providers, 3 PrEP 
providers, and 7 IPV service providers. Women were recruited from a previous prospective 
cohort study, and healthcare and IPV providers were recruited from previous samples and 
contact lists. The qualitative data was analyzed in Dedoose using the framework method. 
Results: Findings suggest that lack of knowledge of both patients and providers is a key barrier 
to PrEP uptake. Women were concerned about logistical factors, such as cost, insurance 
coverage, adherence, and side effects, along with having competing priorities. Providers were 
concerned that a woman’s safety was at risk, and wanted to ensure that women would have tools 
to help conceal PrEP use from partners. Conclusions: Expanding awareness and education for 
PrEP is necessary for both patients and providers. Marketing campaigns for PrEP should include 
women. Future research should continue to examine alternative delivery methods for PrEP, in 
order to combat barriers of adherence and concealment. Research should also look into how 
providers can best work with each other in order to ensure that care and proper treatment can be 
provided to a woman’s entire health profile. 
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Intimate partner violence (IPV) is not only a serious public health issue that 
disproportionately affects women and girls in the United States, but it is also an issue that has 
been associated with HIV susceptibility and acquisition. IPV consists of any physical, sexual, or 
psychological violence or aggression by a current or former intimate partner.14 Recent 
epidemiological data suggest that 43.6 million women (36.4% of women) in the United States 
have experienced rape, physical violence, or stalking by an intimate partner at some time in their 
lifetime.31 IPV can increase a woman’s risk for contracting HIV.6, 11, 12,19,23,29, 35,36,37, 38 For 
example, using a nationally representative sample, one study found that women who had 
experienced IPV in the past year were more than three times more likely to have a diagnosis of 
HIV, as compared to those who had not experienced IPV within the past year.29  Also, a 
longitudinal ecological study found that states with a higher prevalence of IPV also had a higher 
prevalence of HIV.36 In fact, when states had poor protective policies for IPV, the link between 
IPV and HIV was stronger.36 
Abusive relationships can create a context that limits women’s sexual autonomy, making 
it difficult to refuse unwanted risk behaviors that increase her risk of HIV.15  For example, 
women who experience IPV are more likely to report behaviors such as injection drug use, 
transactional sex, and condomless sex as compared to women without IPV experiences.21 More 
specifically, women who experienced IPV have shown to be six times more likely to have 
inconsistent condom use as compared to those who have not experienced IPV.23 These HIV risk 
behaviors are prevalent among women in abusive relationships, in part, because of the limited 
ability to refuse sex or negotiate condom use with male partners.19 Research also suggests that 
abusive male partners are more likely to be engaging in risky sexual behaviors such as partner 
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concurrency and refusal to use condoms, which can heighten women’s risk for HIV.3  
Compounded with a woman’s lack of negotiation of safer-sex practices, forceful sexual 
intercourse can often impair the vaginal membrane, thus increasing a woman’s risk of HIV.12 
Given the significant susceptibility of HIV among women experiencing IPV, research efforts 
must focus on the development and expansion of women-controlled HIV prevention methods for 
this vulnerable population. 
 Truvada, a combination of two HIV medicines (tenofovir and emtricitabine), was 
approved by the FDA to be used as pre-exposure prophylaxis (PrEP) in 2012.26  Currently, PrEP 
is a daily oral medication that can be taken by a person who is HIV negative in order to reduce 
HIV transmission. PrEP works by preventing HIV from reproducing within the body,  and has 
the ability to lower one’s risk of HIV by more than 90%.25 PrEP has the potential to be one of 
most innovative women-controlled HIV prevention methods to date,2, 16, 18, 20, 32 especially for 
women who experience IPV.10, 34,35,37 PrEP may allow women to independently be in control of 
their HIV susceptibility because women do not have to negotiate their use of PrEP with a partner 
as opposed to male condoms.3 PrEP also does not need to be taken at the time of sexual activity, 
which can allow women to take this pill at a convenient and discrete time.3 
Despite the clear unmet need for partner-independent HIV prevention among women 
who experience IPV, current PrEP research and clinical practice has overlooked the importance 
of IPV. For example, the CDC Clinical Practice Guidelines for PrEP recommend PrEP for adult 
heterosexually active men and women who are at substantial risk of HIV acquisition.33 
Substantial risk in this case is defined as having an HIV-positive sexual partner, having high 
numbers of sexual partners, a recent bacterial STI diagnosis, a history of inconsistent or no 
condom use, participating in commercial sex work, or if an individual is in a high HIV 
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prevalence area or network.33 While some of these risk factors may be present within an abusive 
relationship, the risk behavior assessment for heterosexual men and women used by clinicians 
for PrEP recommendations does not specifically include questions regarding IPV.33   Primary 
care practitioners, as well as HIV service providers have noted that the CDC clinical guidelines 
are how they determine one’s HIV risk.10 However, the current indicators for HIV risk, as stated 
above, often overlook individuals experiencing IPV. This is in part due to the fact that 
individuals experiencing IPV often do not know their partner’s HIV status or risk behaviors, and 
therefore would appear ineligible for PrEP. One study found that women experiencing IPV were 
afraid to question their partner’s infidelity for fear of resulting violence.7,24 Unfortunately, 
without a woman knowing her risk due to her partner’s status or behaviors, she may be found 
ineligible for PrEP.      
PrEP presents an opportunity for women to take control of their sexual health and protect 
themselves from acquiring HIV.3 Not only has PrEP proven to be extremely effective, but it does 
not depend on a partner’s knowledge, consent, condom use, or potential lack of viral 
suppression.3,5 One study found that 77% of women would be willing to take oral medication to 
prevent HIV acquisition.34 A second nationally representative sample found that young women 
who experienced IPV were more willing to seek PrEP services than those who had not 
experienced IPV.28 Further, focus groups of women conducted in six cities in the United States 
found that women are willing to look toward their primary care practitioners and reproductive 
health providers for PrEP information and services.1 Despite the utility of PrEP, women only 
represent 4.6% of PrEP users nationally.30 To date, research has sought to understand the 
perceptions and concerns of PrEP among women1,3,4,5,8,27 However, research understanding 
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provider’s perspectives is a missing but necessary component to gain the full picture of a 
woman’s care and treatment. 
This study first sought to understand the attitudes and perceptions of barriers to PrEP 
uptake, adherence, and persistence from the perspectives of women experiencing IPV, as well as 
healthcare providers and IPV service providers that these women most often come into contact 
with. Persistence can be defined as maintaining the necessary requirements per CDC 
recommendations.13 This includes not only adhering to medications, but also being testing for 
HIV and other STIs every three months, and creatinine testing every six months.13 After 
discussing the barriers, participants provided recommendations and solutions for how to combat 
the noted barriers, in order to enhance PrEP care for women experiencing IPV. Using a 
systematic approach, this study incorporates perspectives of providers who frequently come in 
contact with women who experience IPV as well as the women themselves. PrEP providers 
represent a key group of individuals most responsible for prescribing PrEP. Reproductive health 
providers are a critical component to PrEP uptake as women may feel more comfortable 
discussing their sexual and reproductive health with these providers.3 This is because women 
experiencing IPV may have consistent reproductive health providers who already know their 
history. IPV providers are another group that can provide insight to potential barriers and 
solutions, as they may have more insight into the circumstances that women experiencing IPV 
face. Comparing the voices of women experiencing IPV, and providers of PrEP, IPV, and 
reproductive health specialties can help inform a better understanding of how to develop 





A systems perspective was used to incorporate the views of all stakeholders that may take 
part in a woman’s PrEP care, thereby fully understanding the insights of both patients and 
providers. This systems perspective takes into consideration all of the moving parts required to 
facilitate PrEP uptake, adherence, and persistence of women experiencing IPV. Seven Intimate 
Partner Violence (IPV) providers, 5 Reproductive Health providers, 3 PrEP providers, and 19 
women experiencing IPV were interviewed.  
Women experiencing IPV were recruited from an existing prospective cohort study 
examining associations between IPV and engagement in the PrEP care continuum.37,38 A small 
subset of women with IPV experiences were asked to participate in the current qualitative study 
after completion of the quantitative cohort study. Participation occurred on a date separate from 
that of the quantitative cohort study completion. Women were eligible to participate if they were 
between the ages of 18 and 35, could speak English and/or Spanish, lived in Connecticut, fully 
completed the cohort study, and reported at least one of the substantial risk factors stated in the 
2017 CDC Clinical Practice Guidelines for PrEP as stated above. These women provided verbal 
informed consent in order to participate, and were compensated $25 for their time. Qualitative 
interviews of women experiencing IPV were conducted either in-person or over the phone, lasted 
between 10-75 minutes, and were audio recorded. The audio recordings were then uploaded into 
Dedoose and coded directly from the audio files, without transcription. Participants were given 
ID numbers in order to provide anonymity. IRB approved all methods and procedures. 
Demographics of the women experiencing IPV can be found in Table 1.  
The content of the interview guide for women experiencing IPV included relationship 
dynamics; communication about HIV/STD prevention; thoughts, attitudes, experiences with 
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PrEP; and future behavior change to initiate or maintain PrEP use. Interviews were semi-
structured, and interview guides were tailored to women experiencing IPV. 
In order to recruit IPV providers, researchers reached out to an IPV organization list 
provided by the Connecticut Coalition Against Domestic Violence (CCADV). PrEP providers 
were attained through a Connecticut Department of Public Health (DPH) list, and researchers 
used an existing network of Reproductive Health providers from a previous study that looked at 
relationship attachment and postpartum care.22 The audio files were transcribed verbatim and 
then the text transcripts were imported into Dedoose for coding.  
Providers gave verbal consent. Qualitative interviews were performed either in-person or 
over the phone, and lasted between 40-100 minutes. Each provider was entered into a raffle to 
receive a $100 gift card. One gift card was given to a Reproductive Health provider, one to a 
PrEP provider, and one to an IPV service provider. Provider demographics can be found in 
Table 2. Again, participants were given ID numbers in order to provide anonymity, and IRB 
approved all methods and procedures. 
The content of the interview guides for providers included knowledge of and experiences 
with trauma-informed care; IPV knowledge and procedures; HIV risk perception and services 
among IPV-exposed women; PrEP knowledge, care, and attitudes; providing PrEP support to 
IPV-exposed women; and inter-organizational and organizational barriers. Again, interviews 
were semi-structured, and interview guides were tailored to each population interviewed. 
The current study was focused on the perceived barriers and possible solutions to PrEP 
uptake, adherence, and persistence, and therefore a majority of the results were from questions 
related to PrEP knowledge, care and attitudes, and providing PrEP support to IPV-exposed 
women (for providers), and thoughts and experiences as well as future PrEP behavior change 
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(for women experiencing IPV).  For example, regarding IPV and PrEP providers, questions 
included “what are some barriers women in abusive relationships may experience related to PrEP 
management?” For women experiencing IPV, questions included “what are some reasons why 
you haven’t got PrEP yet?” with follow-up questions including “what are some things that would 
make it hard or easy for you to get PrEP?” 
 
Data Analysis 
The framework method was used in order to analyze the semi-structured interviews 
and draw both descriptive and explanatory conclusions.17 The framework method entails 
identifying similarities and differences among qualitative interviews of the same group, and then 
working to find additional similarities and differences between groups.17 In this case, the analysis 
was done among individuals within each provider group (IPV, Reproductive Health, and PrEP), 
and among the women experiencing IPV, and then comparisons were made.  
The questions during the interviews did not simply ask about barriers and solutions to 
PrEP uptake, adherence, and persistence, but also about the general marketing, knowledge, and 
awareness of PrEP logistics and resources. The answers to these questions were then categorized 
under barriers or solutions, to create themes for each provider group and women experiencing 
IPV, as well as any cross-cutting themes across providers and women experiencing IPV. 
If women experiencing IPV or providers were unaware of PrEP, interviewers 
described the purpose and logistical information for PrEP. These themes were used as the basis 
of our coding tree. The codebook was developed by a multidisciplinary research team. The 
research team went over several transcripts and discussed codes until consensus was reached. 
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Discrepancies were reconciled through discussions with the multidisciplinary team. Transcripts 
were coded by research team members TCW and AC.  
  
Results 
Several themes emerged from the analysis. The results section can be separated into 
the two main themes of barriers and solutions. Within barriers, sub-themes include individual-
level barriers (lack of knowledge, competing priorities, and side effects), relationship-level 
barriers (perceived susceptibility, and partner involvement and lack of autonomy), clinic-level 
barriers (within a clinician visit), and structural factors (lack of focused marketing, stigma, and 
access). Solutions were broken down into the strategies for PrEP uptake, as well as the strategies 
for PrEP adherence and persistence. 
Though the themes discussed in the results section appeared consistent throughout the 
interviews, there were certain concepts that were salient only in specific groups. A 
comprehensive chart of the similarities and differences of themes between groups can be seen in 
Table 3, and a diagram of the overlap among themes can be found in Figure 1.  
Barriers 
Individual-level barriers 
Individual-level barriers refer to barriers that women may personally face that impede 
their ability to begin or continue PrEP. This also includes barriers that individual providers may 
face that would prevent them from effectively delivering PrEP care. 
Lack of knowledge 
The lack of both provider and patient knowledge of PrEP appears to be the initial barrier 
in PrEP uptake, adherence, and persistence. While PrEP providers were familiar with PrEP 
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screening and dissemination, IPV and Reproductive Health providers were less familiar with the 
logistical information related to PrEP including what PrEP is, who may be eligible and how 
much it costs. One IPV provider asked various questions about PrEP, to include: 
So this would be something that someone would take before any.... sort of, um interaction that might be?....Is 
there like an age bracket that’s able to take that?....What’s the cost? (IPV Provider 1) 
 
This IPV provider discussed her unfamiliarity with the knowledge and resources needed to 
provide PrEP: 
I don't know a lot of information about like the processes or payment or – you know, I mean, I know to – to refer 
people to – to {a local clinic}  if there's concerns about – about payment, but, I guess I don't feel like we have 
kind of enough resources to provide sufficient support (IPV Provider 1) 
 
Unfortunately, it is difficult for women to be knowledgeable of PrEP when their providers are 
unsure how exactly to handle situations in which PrEP may be a suitable option. An alarming 
majority of women interviewed (N=11) had never heard about PrEP until participating in this 
study, where PrEP was defined and introduced, and a few noted: 
I was like is this real? Or are they just doing like a study…like I wasn’t sure if this was for study purposes or if 
this was really real… I didn’t know that such thing existed, I was like wow (Woman 402) 
 
A PrEP provider noted how patients are very unaware of PrEP, even when it is brought up in 
conversation: 
People aren't aware of what PrEP is. I mention it to people too in my encounters, it's more, mostly that I ask, 
"Should you have a partner, and is your partner aware that there's prophylaxis available in the form of a pill?" 
Most of the times they'll say, "No." So, people are not aware, so we talk about this a lot at our meetings that the 
educational effort and the awareness needs to be wrapped up to a much higher level (PrEP Provider 2) 
  
These knowledge gaps at the patient and provider level proved to be a barrier to PrEP uptake for 
women experiencing IPV, since both women and providers were too unfamiliar with PrEP to 
raise the issue during a clinical encounter. 
Competing Priorities 
Competing priorities refer to concerns or commitments that may take precedence 
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over receiving PrEP care, or simply feeling too busy. For individuals who were aware of PrEP, 
various personal barriers such as fitting appointments into their schedule or remembering to 
make appointments were mentioned. For example, one woman experiencing IPV mentioned how 
various other priorities impeded her ability to talk to her doctor about PrEP: 
When I first heard about it I was like okay I'm gonna talk to my doctor, I'm gonna do it, I'm gonna do it, and 
then a million other things happened and it was just like I was just like uhhhh, I'm gonna wait (Woman 463) 
  
In addition to balancing competing demands, women and providers felt that adherence to a  
daily regimen and attending visits would be burdensome. 
It's always hard to have people remember to take a pill every day, so [laughs] we confront 
that on the contraception road a lot, but there – nowadays, there's, like, all kinds of great things 
like apps to remind you to take pills and all of that. I think that, yeah, it's just those same 
sorts of things that exist for other kind of medication or follow-up that you need, and all of those things are hard 
and even harder when you're in an abusive relationship. So, unfortunately, I don't – I don't see one thing that 
would make this easier than the other things that those patients – those patients really need to – for their care 
(Reproductive Health Provider 1) 
 
       For me it would just be because I forget to take pills (Woman 463) 
 
Side Effects 
In addition to time constraints, potential side effects that individuals may encounter 
while on PrEP were often mentioned by women experiencing IPV as reasons to not use PrEP. 
I think just in general I’m concerned of side effects, like when I was first on the birth control pill 
there were a few side effects like weight gain and mood swings and you know, so that always 
concerns me…I’d like to know, you know, more about the side effects of it before I would. You know, like any 
other medication (Woman 509) 
  
Another woman noted how she would have no tolerance for harsh side effects:  
If every time I take it, I feel sick to my stomach and it’s not getting better, then I wouldn’t want to 
continue that. No I’m sure nobody would…But if my life continues on as normal, like my body still 
shows the same, I will continue to take it. But if there’s any effects, side effects, I’m not going to 
continue to take it…And again, if there’s any discomfort for me, I don’t want it. I’m not gonna refer it. But, you 




Relationship-level barriers refer to barriers related to either the dynamic of a 
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relationship that prevents a woman from feeling at-risk of acquiring HIV, or a partner’s influence 
and involvement. 
Perceived susceptibility 
Although women experiencing IPV may appear interested in PrEP, they must feel as 
though they are susceptible to acquiring HIV from a partner. Several women expressed reasons 
for not needing PrEP. These include: 1) trusting their partner, 2) being celibate, and 3) stating 
that they would not choose to engage in sexual activities with someone who is HIV-positive. An 
IPV also provider expressed that women experiencing IPV may be feeling several conflicting 
emotions, thus decreasing her perceived susceptibility for HIV: 
There are a lot of situations where our client is simultaneously feeling love and trust for their abuser and 
betrayal and fear and I think that there are just certain things that people don't believe other people will do to 
them, other people they love who will do them (IPV Provider 1) 
   
One woman was currently single and planning to stay celibate, and therefore did not see any 
need for PrEP.  While this may be the case, sexual encounters can occur at any time, and 
women should be prepared when the time comes. This woman also states that she would not 
have sex with someone who has HIV (or AIDS). Unfortunately, future partners may not disclose 
or even be aware of an HIV positive diagnosis.  
Like I said, just not the need for it, obviously I'm not gonna be out here trying to have unprotected sex with a 
whole bunch of people, so I don't need to protect myself from that. And then on the flipside, like I don't see 
myself wanting to date anyone or stay with someone who has AIDS like as difficult as it would be I would 
probably have to separate myself from that person and so I wouldn't need that (Woman 539) 
 
Partner involvement and lack of autonomy 
In addition to perceived susceptibility to HIV as a barrier to PrEP uptake, a partner’s 
interference and a woman’s lack of control over her sexual health and body is an important, and 
potentially dangerous barrier. Many providers expressed extreme fear of a partner finding out 
about PrEP use, and consequential potential violence. 
Well, yeah, I would think like if the woman was living with a person that might be a really difficult 
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situation, in concealing sort of or hiding medications, the fear of what happens when it gets 
discovered, consequences of that. I think it might depend on individual situations. You know, would she be able 
to keep it with her best friend, her neighbor, her, you know, someone that she might see on a regular basis and 
just have a few pills around (PrEP Provider 2) 
 
Ideally, women would be able to conceal PrEP use from their partner, if they felt as if 
disclosing PrEP use would create a violent atmosphere. Unfortunately, as described by the 
following Reproductive Health provider, women who experience IPV may not have the luxury of 
privacy from their partners: 
We talked about ways to kind of try to hide it, but, you know, he checks her purse. He checks her 
pockets. He checks her phone. He checks everything (Reproductive Health Provider 3) 
 
Clinic-level barriers 
Clinic-level barriers refer to any barriers that may occur during appointments with 
patients, both logistically and while speaking with women experiencing IPV. In speaking with 
providers regarding introducing PrEP to patients, there were many clinical barriers that stood in 
their way. To begin, clinicians often felt rushed during their visits, and chose to spend their time 
with patients on other medical needs. One Reproductive Health provider mentioned: 
I think that some barriers are just that – I think sometimes patients, unfortunately, can see that you're sort of 
rushed, and don't always feel like maybe that you have the time to – to listen to everything that they need to say. 
I like to think that I try to create a space for patients to talk about it if they want to. And I try to ask all patients, 
you know, if they're at risk for that, but, I think – I think one of the biggest barriers is time, and sort of patients 
seeing that, even if it's subconscious or they wait a long time to see you and then, you're sort of hurried and it's 
just – it's unfortunate, but it's sort of one of the realities that – that we have in the healthcare system 
(Reproductive Health Provider 1) 
 
When IPV was involved, another Reproductive Health provider explained that safety became the 
only priority, leaving sexual health for another visit: 
So I think that the focus of the visit would shift to more counseling and addressing the intimate partner violence, 
and trying to focus on that and maybe less on the other health concerns. Just so that we can address safety of 
the patient (Reproductive Health Provider 2) 
 
Providers appear to prioritize the perceived needs of their patients in the allotted time. In 
addition, providers may also not be qualified to discuss PrEP with their patients due to lack of 
knowledge, and thus may focus on other topics. However, providers may not want to discuss the 
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sensitive topics, especially with victims of IPV. Many of the IPV providers interviewed 
mentioned how they often felt like they were “walking on eggshells” with their patients: 
I think it's tricky to [pause] – I don't know. We spend a lot of time walking on eggshells with our clients just 
because everything is so – triggering, and we're meeting people for the first time, and then having these really, 
really personal discussions with them. And I think we're really fortunate that our clients are so open with us, 
you know? I mean, there have been maybe a couple times when a client has flat-out refused to – my interview. 
People have certainly refused to answer specific questions, which, you know, is totally understandable. But 
we're constantly kind of playing this – you know, like kind of walking this line between asking as many 
questions as we need to make sure that we have addressed all their needs while also not offending or scaring 
them to the point where they shut down, you know? (IPV Provider 1) 
 
Providers may be hesitant bringing up more touchy subjects, not only because their stories and 
experiences may be deeply personal, but also because individuals may consider appointments a 
sort-of outlet away from their troubles: 
It's tough 'cause you know, I mean, I think a lot of them when they get here they're very happy to be away from 
their situation and quite often, they begin looking again for someone, someone to go out with, someone to have 
a good time with. We see a lot of that. They're not always telling us point blank that that's what's going on, but 
we know that it is, uh, so it's hard to have, uh, a discussion about, you know, being safe, um, if someone's not, 
you know, not having that conversation with you. Um, so, yeah (IPV Provider 6) 
 
Structural-level barriers 
Structural-level barriers refer to larger societal or systemic barriers that make it difficult 
for individuals to 1) feel comfortable accessing care, 2) be able to afford PrEP or attend 
appointments, or 3) be aware that PrEP exists and is relevant to them. 
Stigma 
Perceived stigma surrounding both HIV and PrEP can prevent individuals from talking 
about or seeking out care. This perceived stigma was present in both individuals and 
communities. Many mentioned that HIV is a taboo subject, as one woman stated: 
I don't know I feel like that whole topic of like HIV makes people uncomfortable. Even if you're 
talking about or giving something to help you prevent it I still think it makes certain people feel uneasy, like just 
you know saying that (Woman 473) 
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Stemming from a lack of knowledge, providers felts as if individuals believed that the act of 
taking medication, even if it was Truvada (PrEP), was because someone has HIV, not to prevent 
it. One PrEP provider stated: 
So, there's still that stigma that, "I can't tell everybody I have this, so, and I don't want to tell everybody I have, 
you know, PrEP because then they'll think I either have HIV," 'cause they don't understand you'd have to take 
more medications than just Truvada if you have HIV. But it looks like – it's a very distinctive blue pill, so 
everybody kind of knows that it's either that or it's Valtrex for your herpes, and then they don't want to do – 
interact with you either 'cause it means you've got herpes (PrEP Provider 3) 
  
Not only are labels on medications an issue for medication disclosure, but the look or even 
perception of a pill could mislead individuals as for the reason for use. In this case, PrEP is 
associated with HIV, adding to both existing HIV stigma but also to stigma surrounding the 
purpose of PrEP.   
Access 
In addition to the stigma surrounding HIV and PrEP, access was a common structural 
barrier mentioned by both providers and women experiencing IPV. Access specifically 
referred to appointment transportation, access to insurance that would cover PrEP, and 
whether PrEP would be affordable to women. A PrEP provider mentioned cost as a 
foreseeable barrier, not just for PrEP medication, but for the entire clinician visit process:  
And obviously, one of the biggest barriers is the cost. So, it's a cost for you to come to see someone, and then 
obviously the cost to cover the medicine. At first we were afraid that insurers were just going to deny it. But 
since it's been FDA approved, we're pleasantly surprised that's not such a huge obstacle. There are still the 
issues of copays and people who can't afford some of the copays. So, I got a gentleman the other day, his copay 
was $600.00. But there are mechanisms to deal with that. So we have to make people aware that there are 
various ways of handling that (PrEP Provider 2) 
 
As described by this provider, PrEP is often covered by insurance, and payment plans can 
exist for individuals who cannot afford their copays. However, individuals must be 
knowledgeable of PrEP before they are able to learn specific information such as PrEP cost 
and coverage.  After women overcome the initial hurdle of learning about PrEP, the next 
barrier becomes learning the logistical information, and often one of the most important 
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logistics is cost. One woman stated that before she would be interested in taking PrEP she 
wanted to know: 
Just the cost. Like how much does it cost? And I wonder, will my insurance cover that? Will 
they look at it as if it is a contraceptive method? Because I know for birth control my insurance covers for that. 
But I remember they had to call the insurance before I can even get the type that I'm on. So I wonder like will 
my insurance cover it? Or how will they give you that in terms of cost? (Woman 473) 
 
A final access barrier is transportation. Structurally, individuals need to make more than one 
appointment for intakes and follow-ups, and for some, transportation is an issue. An IPV 
provider acknowledged the previous barrier, but continued to say how transportation inhibits 
individuals from following through on appointments: 
Insurance, but you know, I look at the huge thing is transportation. Even getting some clients to think about 
birth control, even getting some clients to self-care, going for checkups, is very, very challenging (IPV Provider 
2) 
 
Attending an appointment often depends on both the distance an individual is from her 
clinician, as well as her ability to have or use a car. Women experiencing IPV may not make 
appointments if they know transportation will be an issue.  
The transportation. Cuz right now, I recently moved from my boyfriend's. And to where my doctor is, it's like an 
hour walk. Because I don't have a car right now (Woman 463) 
 
Lack of focused marketing 
A final structural barrier was marketing. More specifically, marketing either does not 
exist, or is targeted often solely for men who have sex men. Women may not feel susceptible to 
HIV, if the only PrEP marketing is to groups other than women. The current social narrative 
surrounding HIV is that men who have sex with men (MSM), and people who inject drugs 
(PWID) are the only individuals at risk for HIV acquisition. Unfortunately, this misinformation 
prevents women from understanding their true risk of HIV. 
The lack of marketing on TV, in clinician’s offices, and otherwise can also bring doubt 
among patients when they finally learn about PrEP and realize they were never informed.  
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Providers acknowledge that current advertisements are geared toward men, which may 
exacerbate a low perceived susceptibility of HIV. In this case, women may not feel as if other 
women in general are at risk of acquiring HIV, or if PrEP would even be a suitable option, due to 
the lack of marketing toward women. A PrEP provider described this issue: 
I think with some of our initial marketing if you look at most PrEP posters that you see, most of them are 
depicting men, so then you even wonder, is the perception among women is that this is something they should 
also be learning about or not? (PrEP Provider 1) 
 
This concern was supported by women experiencing IPV. A woman stated: 
 
I don't know, maybe just being new and the first thing I had seen of it was like a male couple so it 
didn't stick that out like maybe I need it for my relationship. That may have like changed, like I just 
set the tone in my mind that it was mostly for homosexuals, even though I know it's not (Woman 444) 
            
Solutions 
Strategies for PrEP Uptake 
 Strategies for PrEP uptake refer to methods and practices that can be taken to help 
women experiencing IPV engage in PrEP care and begin treatment. The first strategy to increase 
PrEP uptake is to increase the awareness and education of providers and patients. It is critical 
that providers are knowledgeable about the logistics of PrEP, such as the eligibility criteria, 
cost/insurance, efficacy, and side effects. As noted by an IPV provider: 
Domestic violence victims can be incredibly resourceful and able to juggle a huge amount of things under a 
huge amount of stress. But she can't consider everything, and so it's really helpful to be able to talk through that 
kind of thing. And so if she's able to just come in and the provider – is thinking about more than just the 
prescribing and monitoring of this medication, but also thinking about how it's going to affect when she comes 
home, then that could be really helpful and important (IPV Provider 1) 
 
Providers need to be willing to conduct routine sexual histories with patients and universal 
education on sexual risk reduction skills. Further, women experiencing IPV expressed their 
interest in learning about PrEP not only from providers, but also from women who have been 
taking PrEP, to truly learn what the experience is like. One woman would like to know: 
Who has taken it to see if they're really happy with the pill, you know, and see if it really works, because I'm 
quite sure there's people out there that loves someone with HIV and probably taking this pill, and there has to 
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be a recording or study or research, or more studies online, you know. I think I would get my information from 
there and from my doctors, anything that I really wanted to know (Woman 496) 
 
After women are aware and informed of PrEP, they may be interested in using PrEP as a method 
for self-protection. Not only can PrEP prevent HIV, but it can also empower women to take 
control of their bodies and their sexual health. One PrEP Provider explains how PrEP can help 
women in relationships where negotiating condom use is not an option: 
The actual risk of HIV infection but also the psychologic benefits that being on PrEP may give them a greater 
sense of safety – we use the word empowerment. It may give them a sense that this is something that they can 
control where they can't control condom use, they can't just necessarily just hide that they're using a female 
condom (PrEP Provider 1) 
 
Many of the Reproductive Health providers felt the same way about the empowering nature 
of PrEP use for women: 
But I think it's important to have it as an option and to be able to provide it to our patients who are high risk 
and who are interested in taking this other daily pill. It's something that they can control, which empowers them 
more. And a lot of these patients need some sort of kind of self-empowerment, right. Something that they can 
control if they can't control other parts of their life. So, I do think it's an important part of it (Reproductive 
Health Provider 3) 
 
To address the marketing barriers, one woman felt as though birth control and PrEP should be a 
simultaneous conversation: 
I feel like we should market it like they market birth control. Make it seem like okay well you know, when you 
get your birth control, why not get PrEP as well? You know it's something that you can use. I think if it was 
marketing in conjunction with that, people would look at it like okay, well this is something that I need, you 
know just, whatever, just like I need my birth control (Woman 473) 
 
More broadly, women also just want to see advertisements for PrEP that included women like 
them. Not only could this help alleviate some stigma, but it could also show women that PrEP 
exists as a viable option for them. 
Maybe advertise it more. Make it something that's brought up at normal doctor’s appointments. Like if you go 
for birth control or something of that nature. Yeah I would just suggest advertising it in like maybe magazines, I 
think that females would come across (Woman 444) 
 
Another suggested solution to increase PrEP uptake was to make it available in a broad array of 
service organizations. Individuals expressed the desire to have PrEP widely available at non-HIV 
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clinics, or even anonymously. At one OBGYN clinic, this suggestion is actually going to be 
tested out: 
So, we actually sort of put the steps into motion, and we're actually gonna start providing it to patients at the – 
at the OBGYN clinic, 'cause we found that she wasn't comfortable going to the HIV clinic, that she just – she 
knew a lot of people in the health system, and didn't really feel comfortable doing that, and felt more 
comfortable just getting her care with us, her established doctors (Reproductive Health Provider 1) 
 
Providing PrEP in primary practitioner or OBGYN offices may help to alleviate some access 
issues, since women may be more familiar and accustomed to attending these offices. In 
addition, it may be easier to conceal the reason for a visit if a partner needed to drop a woman off 
for an OBGYN visit, as opposed to a drop off at an HIV clinic: 
I think one way is to expand services to other places like the OBGYN office or family medicine office so they're 
not specifically going to a certain clinic. So, if their partner comes, "Well, I'm – I'm going to get a pap smear." 
You know, it's definitely easier to say, "I'm going to get a pap smear" then, "Well, why are you going to this 
medicine clinic – " you know, " – this infectious disease clinic?" (Reproductive Health Provider 1) 
 
Not only do initial visits require appointments, but follow-up tests often require women to return 
to the provider’s office routinely. If separate, more convenient laboratories were available for the 
follow-ups, one Reproductive Health provider noted that it would be much easier: 
Having it not necessarily them having to come to our office to do it but finding a local site that 
could do it {follow-up tests} instead of – something closer to them that would make it more 
feasible (Reproductive Health Provider 2) 
 
Finally, women experiencing IPV cited a desire for anonymous services so as to not feel 
judged: 
I don't really know her {provider} that well, so I would feel, not crazy, but I would just wonder like, I wouldn't 
feel so comfortable like talking to her about that. Like if there was something I could do like maybe like 
anonymously, like I don't know. Like If I could just go. I don't know if that made sense. I guess I don't want to be 
like labeled. Like you know, is this person, like are they really sexually active? Why do they need that you 
know? (Woman 473) 
 
Another barrier that was mentioned was that providers are not asking the right questions, if 
asking questions at all. Creating a “clinical checklist” to screen individuals and then provide 
options would allow PrEP to be discussed more, and would allow providers to gain a better 
understanding of what is going on with their patients. A Reproductive Health provider 
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expressed the importance of a clinical checklist in order to productively screen patients, learn 
histories, and provide the best possible care: 
I think that that's something that before we can incorporate PrEP, we have to sort of change our 
paradigm of how we do patient histories, to even get to those patients who might even be at risk. 
Because a lot of patients won't even know to bring it up, so they might not bring up that their 
patient's – their partner's HIV-positive 'cause they don't know that there's anything out there that could change 
that, besides, you know, use of condoms (Reproductive Health Provider 1) 
 
Another suggestion for increased PrEP uptake was to create alternative delivery methods for 
PrEP. Currently, PrEP can only be taken as a daily pill, with required follow-ups. As previously 
mentioned, many individuals find taking a daily pill to be a burden, and this daily act may make 
concealment from a partner more difficult. Suggestions for alternative methods included shots, 
implants, and more: 
You know, if we could do it some way like a Depo shot. Right, like an injection every three months then I think 
compliance would actually be a lot higher. Or even an implant, all the things that we do for a long active 
contraception, if we could do something like that then I think that compliance would go up significantly 
(Reproductive Health Provider 3) 
 
The last suggestion for PrEP uptake is to ensure that clinicians are working together and 
communicating with each other to ensure that participants are receiving safe and quality care. 
Provider collaboration can help for doctors to screen and refer patients to receive PrEP, as well 
as ensure that those who are on PrEP remain in contact with physicians, potentially through a 
domestic violence agency, to guarantee adherence and persistence. One IPV provider explains: 
So it's more likely that doctors are probably not in the position to do that in-depth safety planning. So I think it's 
having the resources to know where to refer them to. And then, you know, we talked – I talked earlier about the 
referral – I'm sorry, the release of information that we have. You know, like, just really staying in contact with 
the, um, domestic violence agency and the – the primary care physician to make sure that they're talking, 
because that's always a missing piece. You've got a lot of people sometimes working with one victim but nobody 
is talking to each other (IPV Provider 7) 
 
Doctors can also work together to screen patients for IPV, and then collaborate to provide well-
rounded care to the individual: 
One thing that does sound very good with it – I would say collaborating with doctors on, again, how to 
recognize intimate partner violence and see, you know, what the issues look like for a lot of people who are 
going through, will probably help service delivery immeasurably (IPV Provider 4) 
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This can be done through provider-to-provider education, in order to learn how to identify 
potential victims, and what steps to then take.   
Strategies for PrEP Adherence and Persistence 
Strategies for PrEP adherence and persistence refer to methods and practices that can be 
taken once an individual has begun PrEP, in order to ensure she is following medication 
procedures and has a safe plan to continue PrEP use. 
Once individuals have the knowledge and ability to start PrEP, it is crucial to combat any 
barriers that may prevent women experiencing from continuing to use PrEP. One of the 
strategies for PrEP adherence and persistence as discussed by participants was to provide support 
systems and resources. These supports range from groups to transportation to advocates and 
more. One IPV provider discussed how support groups may encourage continuity of PrEP use: 
I think support groups are great, meeting other people who might be in similar situation as you or learning why 
they decided to do it. It might help to make someone who's apprehensive about trying it use it or – I don't know. 
So I think support groups are good (IPV Provider 3) 
 
Supports can also be present in the delivery of care, and the relationships built between patient 
and provider, as mentioned by one Reproductive Health provider. This could include a caring 
clinician who ensures that individuals are reminded of their appointments, or a policy to ensure 
patients are contacted for reminders. Understanding that one’s medical experience is complex 
and many challenges can arise, providing transportation was suggested by one IPV provider: 
Offering them transportation, maybe bus tickets or – or transportation to and from, but also then setting up a 
plan for when they leave, what's the plan gonna be. You know, how are they gonna get there, how are they 
going to,  – and then giving them to wherever the program is or wherever they're gonna maybe relocate to, 
make sure there's a provider they're leaving can refer them to a provider where they're going to be going. 
'Cause many of our victims coming into shelter may not stay in the area. They may go on to another area, so 
can that be transferred to another doctor or another (IPV Provider 2) 
 
Transportation support would be one example of how providers could treat the entire patient and 
her needs. Other suggestions by IPV providers include ensuring that safety planning is available: 
I mean, ideally I think it would be really great to have, like, an –  advocate at the places that provide PrEP who 
is able to go through kind of safety planning with the client before they were able to participate in PrEP or even 
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just like maybe – maybe even if just providers called the hotline with a client, if the client seemed to have safety 
concerns, and they could talk that way, or – (IPV Provider 1) 
 
And a final suggestion by an IPV provider was that patients be provided with a network of 
supports, including clinical staff and personal ties. 
Like I said, one of the different, I would say client demographics that we see are people who are interested in 
services, need support groups, want to talk about what's happening but aren't yet ready to leave their abuser, 
and if that's the case having a good support system, of physicians of nurses of every person who's going to be in 
the client's life makes a tremendous difference around what the actual outcome is (IPV Provider 4) 
 
PrEP adherence and persistence also require that women be able to conceal their PrEP use from 
partners, if disclosure would pose a problem for a woman’s safety or for her continued PrEP use. 
All providers had similar ideas regarding tools for concealment, which all stemmed from a desire 
for safety planning. One IPV provider stressed the importance of having a plan before starting 
PrEP, and figuring out how to not only hide the medication, but how one would plan to attend 
the necessary appointments: 
Taking the drug and where they're going to be, keeping it, and how they're going to take it and how they're 
gonna get back to those appointments. You know, whether that safety planning and coordination happens in 
conjunction with a domestic violence agency, of course, would be preferable, but also maybe the doctors 
themselves can do a little bit of safety planning around that (IPV Provider 7) 
  
Finally, the forms that are given at visits often have the medications and definitions clearly 
printed on them. A Reproductive Health provider notes the difficulty of the necessary follow-up 
visits, but provides a suggestion for naming these appointments differently, and again making the 
medication look less obvious: 
Think anything that we could do to make us a not suspicious medication or to make the frequent visits, you 
know, as easy as possible for them would increase the compliance a lot. So, if we had a good way of naming the 
visit something else and knowing providers that this is what it is. But, I don't know, you know, compliance check 
every three months, or whatever they call it is, you know, it says on their printout, Truvada's on their printout 





To our knowledge, this study is the first to examine perceived barriers and solutions to 
PrEP uptake, adherence, and persistence from the perspectives of healthcare providers, IPV 
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service providers, and women experiencing IPV. Understanding the perspectives of these 
women, along with the providers that they interact with most, can allow for quality multifaceted 
approaches to PrEP care. 
The major themes expressed by women experiencing IPV relate to individual and 
logistical barriers to PrEP uptake, adherence, and persistence. Consistent with previous studies, 
women were generally unaware of PrEP and its effectiveness prior to participation in this 
study.2,3,38 In addition, women experiencing IPV mentioned barriers such as side effects they 
might face, potential costs of the medication and whether insurance would cover it. These 
findings have been duplicated in the literature,1,2,4 along with the desire to have a variety of 
delivery methods available, as opposed to a daily oral medication.2,38 Women often noted how 
they did not feel at-risk for HIV, and therefore did not need to seek PrEP care. Competing 
priorities were often noted as a barrier, as individuals stated that they were too busy to seek care. 
Though not explicitly concerned for their safety, women experiencing IPV were worried that 
their partners would question why they felt the need to be on PrEP. On a broader level, women 
often did not feel comfortable talking about PrEP or HIV because of the stigma attached. Women 
noted that their providers rarely, if ever, mentioned PrEP. Finally, women noted that the lack of 
marketing of PrEP towards women like them, made them feel PrEP was not a solution for them.     
Healthcare providers (PrEP and Reproductive Health providers) placed a strong emphasis 
on safety, along with partner awareness and structural barriers, when discussing their perceived 
barriers to PrEP care. Participants mentioned the need for providers to be focused on a woman’s 
safety before offering them PrEP, and to be extremely mindful of a woman’s potential fear of 
PrEP disclosure and resulting violence. Tools for concealment were mentioned by both PrEP and 
Reproductive Health providers, to help individuals prevent their partners from withholding 
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medicine, asking questions, or inhibiting one’s ability to take the medication. Suggestions 
included adjusting the labeling and packaging, not so much to ensure that partners did not know 
what was going on, but to make it less obvious that “Truvada” was for PrEP. Again, cost and 
insurance came up as well as the ability for women to take control of their sexual health. 
Reproductive Health providers also mentioned adherence to a daily regimen and the required 3-
month follow-up as barriers to PrEP. Most of the solutions to barriers would be structural 
changes, such as adjusting HIV stigma, providing PrEP in non-HIV clinics, and having resources 
to facilitate support for individuals, ranging from peer and family support to appointment 
reminders and follow-ups. Regarding the daily regimen, Reproductive Health providers 
recommended alternative delivery methods. Providers also need to be comfortable discussing 
PrEP within visits, as well as persistently asking individuals if they would be interested. One 
suggestion was to have a clinical checklist all providers could use to find high-risk patients. 
Unfortunately, providers stated that often there are conflicting priorities when someone comes in 
for an appointment, such as a UTI, and that patients may feel that providers are rushed and 
therefore do not want to take the time to discuss PrEP. 
 IPV providers, though they did not have much experience with PrEP, centered their 
perceived barriers around a woman’s safety. While IPV providers did mention logistical barriers 
such as where to receive PrEP, how much it costs, and ideal candidates, the focus of these 
providers was to ensure that a woman could conceal her PrEP use and avoid partner disclosure or 
any resulting violence. IPV providers suggested that tools and resources should be available to 
help women experiencing IPV conceal their PrEP use. Provider suggestions for concealment also 
included keeping the medication at someone else’s house. Partner interference was also 
mentioned in the context of control, as providers mentioned that partners often follow patients to 
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visits, control their finances, and are the source of transportation. Within the patient visit, IPV 
providers often felt as if they were already walking on eggshells with their patients, and were 
therefore unsure how to incorporate PrEP. IPV providers noted that their patients had low 
perceived susceptibility, and often did not think about HIV exposure until after a partner would 
disclose his status. Overall, IPV providers did not always feel equipped to discuss PrEP, and 
suggested that a gynecologist may be a better fit for PrEP discussions. Integrating reproductive 
health services and HIV prevention is a suggestion consistent with recommendations in the 
current literature.18 Though IPV providers’ main concern is a woman’s safety, sharing records 
with healthcare providers may allow women to receive well-rounded healthcare and can also 
educate providers on the full picture of each patient. 
Though participants discussed various solutions to noted barriers, a few barriers lacked 
solutions. Barriers that were not addressed in the solutions section include how to increase 
adherence to a daily regimen and follow-up, given that alternative delivery methods do not yet 
exist. In addition, though education should hopefully provide women with the knowledge to seek 
out PrEP, barriers regarding time constraints and competing priorities may still exist. Also, 
combating and reducing HIV and PrEP stigma is a complicated task. Until the broader HIV 
stigma is addressed, women may feel stigmatized as PrEP is a clear extension of HIV, even if it 
is for prevention.9 Providers noted how PrEP could invoke a sense of empowerment, as women 
are able to take control of their sexual health without needing the consent of a partner.  
Results must be interpreted within the context of the current literature. Previous research 
has stated that lack of PrEP knowledge is a large barrier to PrEP uptake.2,3,38 Findings from this 
study highlight the lack of knowledge not only of patients, but of their providers. Women cannot 
learn about PrEP until providers have been educated and are comfortable speaking to patients 
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about PrEP. In addition, many of the barriers described by women center around personal 
factors, such as not wanting side effects or being too busy. Providers, on the other hand, are 
much more focused on safety as a barrier to PrEP care. Though there is not one way to approach 
PrEP care, providers should be cognizant of patient’s interests in partner-independent prevention 
strategies. Many women expressed interest in PrEP, and noted that they may be taking it if the 
medication was mentioned during a provider appointment. PrEP education is not the 
responsibility of the provider alone. Advertisements and marketing should be more inclusive, so 
that women understand that they too are at risk. 
There were many limitations of this study. First, the sample size for providers was small. 
However, it should be noted, that we felt saturation was reached in the provider surveys, since 
later surveys did not reveal any new themes. Providers who participated may differ from those 
who chose not to participate, especially given the low number of PrEP providers (3). In addition, 
the women experiencing IPV were sampled from a previous cohort study related to PrEP, and 
therefore these individuals may not be representative of women outside of the study. All 
participants were also from Connecticut, limiting the generalizability of this study to other areas. 
Further, many of the interview questions asked participants to speculate on hypothetical 
situations, as opposed to on lived experiences. Providers were also asked to reflect on what they 
imagined to be going through the mind of a women experiencing IPV.   
Despite the limitations, this study is one of the first to examine perspectives of not only 
women experiencing IPV, but also healthcare providers and IPV service providers that these 
women most often come into contact with. This study also sought to compare and contrast 
perceived barriers and solutions in order to understand any disconnects between groups. Our 
findings suggest that both patients and providers should be educated on PrEP. This is especially 
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important for providers so that they are able to effectively screen and educate patients. IPV 
screening and counseling must be incorporated into clinical settings that administer PrEP, and 
non-HIV clinics should begin to administer PrEP in order to increase uptake and make 
individuals feel comfortable by receiving care by their consistent providers. PrEP marketing 
must also expand to include heterosexual women, in order for women to understand their risk of 
acquiring HIV and how PrEP can help. Women are interested in learning more about PrEP, and 
potentially starting PrEP, as long as they are aware of the costs, side effects, and necessary 
follow-ups. Providers should keep this in mind, while also continuing to worry about a woman’s 
safety and the best strategies to conceal PrEP uptake, adherence, and persistence from a partner, 
if potential violence may occur.  Future research should continue to examine alternative delivery 
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Table 1. Demographics of women experiencing intimate partner violence 
 N (%) 
Overall 19 (100) 
Age, M (SD) 26.5 (5.8) 
Race and Ethnicity  
Non-Hispanic Black 10 (52.6) 
Non-Hispanic White 3 (15.8) 
Hispanic 3 (15.8) 
Non-Hispanic Other Race 3 (15.8) 
Highest Completed Education  
Less than Bachelor’s degree 13 (68.4) 
Bachelor’s degree or higher 6 (31.6) 
Employment Status  
Unemployed 12 (63.2) 
Employed (full- or part-time) 7 (36.8) 
Income Status  
<$30,000 9 (47.4) 
$30,000+ 10 (52.6) 
Types of IPV experienced in past 6 months  
Physical and Sexual IPV 8 (42.1) 
Physical IPV only 7 (36.8) 
Sexual IPV only 4 (21.1) 
PrEP attitudes and experiences  
Aware of PrEP before study 8 (42.1)  
Intended to receive PrEP 7 (36.8) 
Had a current PrEP prescription 0 (0) 









Table 2. Demographics of providers 






 N (%) 
Overall 15 (100) 
Age, M (SD) 42.1 (12.1) 
Gender  
Female 13 (86.6) 
     Male 1 (6.7) 
     Unknown 1 (6.7) 
Race and Ethnicity  
Caucasian/White 12 (80.0) 
Asian 2 (13.3) 
     Latina 1 (6.6) 
Occupation  
     IPV Service Providers 7 (46.7) 
Reproductive Health Providers 5 (33.3) 
     PrEP Providers 3 (20.0) 
Average years at current organization, M (SD) 6.2 (5.8) 
Average total years of clinical experience (of those 
with clinical experience), M (SD) 
14.9 (11.4) 
Average total years of clinical experience of all 
participants, M (SD) 
9.9 (11.7) 





Table 3. Summary table of themes among providers 
 Theme 
Examples from Healthcare 
Providers 
Examples from IPV 
Service Providers 

















Providers’ and Women’s 
Lack of PrEP Knowledge 
• Reproductive Health Providers 
discussed that many providers do not 
consider PrEP for high-risk women.  
• IPV Service Providers 
discussed their limited 
knowledge of and support on 
the clinical aspect of PrEP 
(e.g., eligibility, payment).  
• Some women illustrated disbelief in 
PrEP. 
• Training on PrEP education and 
implementation in non-HIV 
clinical settings for reproductive 
health and IPV service 
providers.  
Time and Resource 
Constraints 
  • Some women felt as though they 
were too busy or had other priorities 
and therefore could not find the time 
to make it to a provider. 
 
Side Effects   • Women do not want to take PrEP if 
there are harsh side effects, and they 
don’t know enough about it. 
• Giving women PrEP users a 
proper platform to discuss their 
















Perceived susceptibility • PrEP Providers discussed how women 
often did not feel at-risk for HIV. 
• IPV Service Providers 
discussed how women often 
face internal struggles with 
trusting their partners and 
fearing them.  
• IPV Service Providers noted 
how a woman’s trust in her 
partner often leads to lack of 
perceived susceptibility. 
• Women displayed low perceived 
susceptibility. Those in a 
relationship trusted their partners, 
and those that were not in a 
relationship did not think that they 
would have unprotected sex, nor 
would they have sex with someone 
with HIV. 
• Increase PrEP education and 
awareness. 
• Ensure marketing includes 
women in heterosexual 
relationships. 
Partner Involvement and Lack 
of Autonomy 
• PrEP Providers discussed their fear of a 
woman’s partner finding out that she 
was on PrEP and consequential 
violence. 
• Reproductive health providers talked 
about the control and constant 
monitoring that abusers often have in 
relationships, making it difficult for 
PrEP uptake and persistence. 
• IPV Service Providers 
discussed how partners often 
controlled the lives of these 
women. Examples include 
controlling through 
transportation, tracking cell 
phones, and attending 
appointments. 
 • Having providers or advocates 
engage in safety planning with 
their patients to ensure they are 
equipped with hotlines and 
safety strategies. 
















Barriers within a clinician 
visit 
• Some PrEP Providers worry that PrEP 
is not being brought up by providers. 
• Reproductive Health Providers often 
noted that their providers may not be 
equipped to discuss PrEP, or that if 
intimate partner violence was brought 
up, the appointment shifted to safety 
discussions. 
• IPV Service Providers often 
felts as if they were walking 
on eggshells with their clients, 
and therefore were not always 
comfortable talking about 
PrEP or asking sensitive 
questions. 
• Women often noted how there was 
no mention of PrEP by a provider at 
any clinician visit, nor were there 
advertisements present at clinician’s 
offices. 
• Providing a checklist to 
providers can help providers feel 
comfortable discussing PrEP 

















HIV/PrEP Stigma • PrEP providers often noted how stigma 
still exists surrounding HIV, and 
therefore PrEP by association is tied to 
the stigma. 
 • Women discussed how the general 
topic of HIV often makes 
individuals uncomfortable. 
 
Lack of appropriate 
marketing 
• PrEP providers acknowledged that the 
current advertisements for PrEP are 
targeted for men. Women may interpret 
PrEP as something not designed for 
them. 
 • Most women had not heard about 
PrEP prior to this study. Of those 
who had heard of PrEP, some 
believed the target for PrEP was 
same-sex male couples. 
• Expanding marketing efforts to 
increase awareness but also to 
include women in the 
advertisements. 
• Using clinician offices as a 
location for advertising. 
Access (cost, insurance, and 
transportation) 
• Reproductive Health Providers 
mentioned barriers for uninsured 
individuals.  
• PrEP Providers mentioned how visits 
and follow-ups all cost money, on top 
of the cost of the medicine. They also 
sometimes worry that insurance will not 
cover it. 
• IPV Providers mentioned 
insurance issues, but 
capitalized on transportation 
being a large barrier to 
attending appointments. 
Providers reinforced the idea 
that partner control could be 
hindering access to 
transportation. 
• Women were often concerned about 
the cost of PrEP, as well as whether 
their insurance would cover it.  
• Some women also had no way to get 
to their appointments. 
 
• Offering bus tickets. 
• Encouraging communication 
between patients and providers 
to ensure that patients are able to 
get to appointments and back 
home safely. 
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Figure 1. Venn diagram of salient concepts 
 
 
